AlphaFold2 structures guide prospective ligand discovery
Jiankun Lyu, Nicholas J. Kapolka, Ryan H. Gumpper, Assaf Alon, Liang Wang, Manish K. Jain, Ximena Barros-Álvarez, Kensuke Sakamoto, Yoojoong Kim, Jeffrey F. Diberto, Kuglae Kim, Isabella Glenn, Tia A. Tummino, Sijie Huang, John J. Irwin, Olga O. Tarkhanova, Yurii S. Moroz, Georgios Skiniotis, Andrew C. Kruse, Brian K. Shoichet, Bryan L. Roth
Science May 16, 2024 DOI: 10.1126/science.adn6354 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Prospective docking study Peer reviewed |
|---|---|
| Keywords | Docking animal Computational biology Affinities Stereochemistry Ligand biochemistry Amino acid residue Receptor Biophysics Peptide sequence |
| Citations | 145 |
| Key points | Docking against unrefined AlphaFold2 models of the σ2 and 5-HT2A receptors yielded hit rates and affinities comparable to those from docking against experimental structures. |
Abstract
AlphaFold2 (AF2) models have had wide impact but mixed success in retrospective ligand recognition. We prospectively docked large libraries against unrefined AF2 models of the σ 2 and serotonin 2A (5-HT2A) receptors, testing hundreds of new molecules and comparing results with those obtained from docking against the experimental structures. Hit rates were high and similar for the experimental and AF2 structures, as were affinities. Success in docking against the AF2 models was achieved despite differences between orthosteric residue conformations in the AF2 models and the experimental structures. Determination of the cryo–electron microscopy structure for one of the more potent 5-HT2A ligands from the AF2 docking revealed residue accommodations that resembled the AF2 prediction. AF2 models may sample conformations that differ from experimental structures but remain low energy and relevant for ligand discovery, extending the domain of structure-based drug design.
Citations in the library
Cited by 7
- The structural diversity of psychedelic drug actions revealed. Nature Communications March 19, 2025
- The science of psychedelic medicine. Nature Medicine February 6, 2026
- Chemistry/structural biology of psychedelic drugs and their receptor(s). British Journal of Pharmacology October 2, 2024
- Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond. Journal of Medicinal Chemistry May 1, 2025
- Structure-based design of subtype-selective psychedelic analogs Nature Communications September 17, 2026
and 2 more in the library
Cites 4
- Structure-based discovery of nonhallucinogenic psychedelic analogs Science January 27, 2022
- Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD. Neuron October 5, 2022
- Molecular insights into the regulation of constitutive activity by RNA editing of 5HT2C serotonin receptors Cell Reports August 1, 2022
- Bespoke library docking for 5-HT2A receptor agonists with anti-depressant activity Nature September 28, 2022